Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Revolution Medicines, Inc. - Common Stock (NQ:RVMD)

46.55 -0.16 (-0.34%)
Streaming Delayed Price Updated: 1:08 PM EDT, Oct 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Revolution Medicines, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Analysts Raise Price Targets Following Strong Data From Revolution Medicines' Pancreatic Cancer Drug
Revolution Medicines reports positive results from daraxonrasib trials in metastatic pancreatic cancer, with strong response rates and consistent safety data. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Aon To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Earnings Scheduled For August 6, 2025
 
Via Benzinga
Earnings Scheduled For May 7, 2025
 
Via Benzinga
A Glimpse of Revolution Medicines's Earnings Potential
 
Via Benzinga
Earnings Scheduled For February 26, 2025
 
Via Benzinga
Top 3 Health Care Stocks That Could Blast Off In December
 
Via Benzinga
This Parker-Hannifin Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
 
Via Benzinga
Revolution Medicines Inc (NASDAQ:RVMD) Reports Q2 2025 Earnings Miss, Shares Drop 4.5% After-Hours
Revolution Medicines (RVMD) missed Q2 2025 revenue and EPS estimates, reporting $0 revenue and a -$1.31 loss. Shares dropped 4.5% amid investor concerns, despite progress in Phase 3 trials for... 
Via Chartmill
Topics Earnings
This GitLab Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
 
Via Benzinga
Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors
From Summit Therapeutics Inc.
Via Business Wire
Revolution Medicines To Advance Lead Cancer Drug With $2 Billion In Funds
Revolution Medicines signs a $2 billion funding deal with Royalty Pharma to support its RAS(ON) pipeline, including daraxonrasib development and launch. 
Via Benzinga
Revolution Medicines To Get Up To $2B For Development Of Cancer Drug From Royalty Pharma
Royalty Pharma will provide up to $1.25 billion to Revolution Medicines in exchange for a synthetic royalty on annual worldwide net sales of Daraxonrasib for a term of 15 years and a senior secured... 
Via Stocktwits
Groupon Posts Upbeat Earnings, Joins Axon Enterprise, Warner Bros. Discovery, MercadoLibre And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Why Is Cancer Drug Developer Revolution Medicines Stock Trading Higher On Monday?
Revolution Medicines shared Phase 1 data showing zoldonrasib's acceptable safety profile in KRAS G12D mutant solid tumors at AACR 2025. 
Via Benzinga
Dow Dips 150 Points; ISM Manufacturing PMI Tops Estimates
 
Via Benzinga
Topics Stocks
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Stellantis, PG&E And Other Big Stocks Moving Lower In Monday's Pre-Market Session
 
Via Benzinga
Top 3 Health Care Stocks That Should Keep You Up At Night This Quarter
 
Via Benzinga
Microsoft To Rally Around 6%? Here Are 10 Top Analyst Forecasts For Tuesday
 
Via Benzinga
Why Helen of Troy Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
 
Via Benzinga
Nvidia, Micron, Arlo Technologies And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
The 7 Most Undervalued Under-$50 Stocks to Buy in June 2024
Undervalued stocks under $50 hold significant appeal, but as every investor knows, value is in the eye of the beholder 
Via InvestorPlace
The 3 Most Undervalued Biotech Stocks to Buy in June 2024
https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate 
Via InvestorPlace
RVMD Stock Earnings: Revolution Medicines Beats EPS for Q1 2024
RVMD stock results show that Revolution Medicines beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Top 3 Health Care Stocks That May Collapse In Q2
As of April 12, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. 
Via Benzinga
Why Ascent Solar Technologies Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Ascent Solar Technologies, Inc. (NASDAQ: ASTI) fell sharply during Wednesday’s session after the company announced pricing of a $6 million public offering of shares at $0.14 per share. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.